[1]刘 璞,高 飞.鞘氨醇激酶2与脑相关性疾病的研究现状[J].医学信息,2021,34(03):46-48,55.[doi:10.3969/j.issn.1006-1959.2021.03.014]
 LIU Pu,GAO Fei.Research Status of Sphingosine Kinase 2 and Brain Related Diseases[J].Medical Information,2021,34(03):46-48,55.[doi:10.3969/j.issn.1006-1959.2021.03.014]
点击复制

鞘氨醇激酶2与脑相关性疾病的研究现状()

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
34卷
期数:
2021年03期
页码:
46-48,55
栏目:
综述
出版日期:
2021-02-01

文章信息/Info

Title:
Research Status of Sphingosine Kinase 2 and Brain Related Diseases
文章编号:
1006-1959(2021)03-0046-04
作者:
刘 璞高 飞
(西安医学院第一附属医院神经内科,陕西 西安 710000)
Author(s):
LIU PuGAO Fei
(Department of Neurology,the First Affiliated Hospital of Xi’an Medical University,Xi’an 710000,Shaanxi,China)
关键词:
鞘氨醇激酶2脑缺血性疾病神经退行性疾病炎症
Keywords:
Sphingosine kinase 2Cerebral ischemic diseaseNeurodegenerative disease Inflammation
分类号:
R742
DOI:
10.3969/j.issn.1006-1959.2021.03.014
文献标志码:
A
摘要:
鞘氨醇激酶2(Sphk2)是维持细胞内鞘脂平衡的关键限速酶与细胞内信号转导酶,参与调节细胞凋亡、炎症与代谢等多种生理功能,其表达或活性的上调与下调,与脑缺血性疾病、阿尔兹海默病、帕金森病等的发生发展密切相关。本文主要综述近年Sphk2与脑缺血性疾病和神经退行性疾病的研究进展,以期为脑缺血性疾病和神经退行性疾病的预防和治疗提供参考。
Abstract:
Sphingosine kinase 2 (Sphk2) is a key rate-limiting enzyme and intracellular signal transduction enzyme that maintains the balance of intracellular sphingolipids, and is involved in regulating various physiological functions such as apoptosis, inflammation and metabolism.The up-regulation and down-regulation of its expression or activity is closely related to the occurrence and development of cerebral ischemic diseases, Alzheimer’s disease, Parkinson’s disease, etc.This article mainly reviews the research progress of Sphk2 and cerebral ischemic diseases and neurodegenerative diseases in recent years, in order to provide references for the prevention and treatment of cerebral ischemic diseases and neurodegenerative diseases.

参考文献/References:

[1]Blondeau N,Lai Y,Tyndall S,et al.Distribution of sphingosine kinase activity and mRNA in rodent brain[J].Journal of Neurochemistry,2010,103(2):509-517. [2]Dimasi David P,Pitson Stuart M,Bonder Claudine S.Examining the Role of Sphingosine Kinase-2 in the Regulation of Endothelial Cell Barrier Integrity[J].Microcirculation,2016(23):248-265. [3]Schuhmann Michael K,Krstic M,Kleinschnitz C,et al.Fingolimod(FTY720)Reduces Cortical Infarction and Neurological Deficits During Ischemic Stroke Through Potential Maintenance of Microvascular Patency[J].Curr Neurovasc Res,2016(13):277-282. [4]Gaire BP,Choi JW.Sphingosine 1-Phosphate Receptors in Cerebral Ischemia[J].Neuromolecular Med,2020. [5]Wacker BK,Freie AB,Perfater JL,et al.Junctional Protein Regulation by Sphingosine Kinase 2 Contributes to Blood-Brain Barrier Protection in Hypoxic Preconditioning-Induced Cerebral Ischemic Tolerance[J].Journal of Cerebral Blood Flow&Metabolism,2012,32(6):1014-1023. [6]Chen JL,Wang XX,Chen L,et al.A sphingosine kinase 2-mimicking TAT-peptide protects neurons against ischemia-reperfusion injury by activating BNIP3-mediated mitophagy[J].Neuropharmacology,2020(181):108326. [7]Song DD,Zhang TT,Chen JL,et al.Sphingosine kinase 2 activates autophagy and protects neurons against ischemic injury through interaction with Bcl-2 via its putative BH3 domain[J].Cell Death&Disease,2017,8(7):e2912. [8]Di G,Wang Z,Wang W,et al.AntagomiR-613 protects neuronal cells from oxygen glucose deprivation/re-oxygenation via increasing SphK2 expression[J].Biochemical&Biophysical Research Communications,2017,493(1):188-194. [9]Dorostkar MM,Zou C,Blazquez-Llorca L,et al.Analyzing dendritic spine pathology in Alzheimer’s disease:problems and opportunities[J].Acta Neuropathol,2015,130(1):1-19. [10]Dominguez G,Maddelein ML,Pucelle M,et al.Neuronal sphingosine kinase 2 subcellular localization is altered in Alzheimer’s disease brain[J].Acta Neuropathol Commun,2018,6(1):25. [11]Lei M,Teo JD,Song H,et al.Sphingosine kinase 2 potentiates amyloid deposition but protects against hippocampal volume loss and demyelination in a mouse model of Alzheimer’s disease[J].The Journal of Neuroscience,2019,39(48):519-524. [12]Couttas TA,Kain N,Daniels B,et al.Loss of the neuroprotective factor Sphingosine 1-phosphate early in Alzheimer’s disease pathogenesis[J].Acta Neuropathologica Communications,2014,2(1):9. [13]Jesko H,Wencel PL,Lukiw WJ,et al.Modulatory Effects of Fingolimod(FTY720)on the Expression of Sphingolipid Metabolism-Related Genes in an Animal Model of Alzheimer’s Disease[J].Mol Neurobiol,2019,56(1):174-185. [14]Ryan BJ,Hoek S,Fon EA,et al.Mitochondrial dysfunction and mitophagy in Parkinson’s: from familial to sporadic disease[J].Trends Biochem Sci,2015(40):200-210. [15]Pyne S,Adams DR,Pyne NJ.Sphingosine Kinases as Druggable Targets[J].Handbook of Experimental Pharmacology,2020(259):49-76. [16]Sivasubramanian M,Kanagaraj N,Dheen ST,et al.Sphingosine kinase 2 and sphingosine-1-phosphate promotes mitochondrial function in dopaminergic neurons of mouse model of Parkinson’s disease and in MPP+-treated MN9D cells in vitro[J].Neuroscience Oxford,2015(290):636-648. [17]Pyszko JA,Strosznajder JB.The key role of sphingosine kinases in the molecular mechanism of neuronal cell survival and death in an experimental model of Parkinson’s disease[J].Folia Neuropathol,2014,52(3):260-269. [18]Phillips GR,Hancock SE,Brown SHJ,et al.Cholesteryl ester levels are elevated in the caudate and putamen of Huntington’s disease patients[J].Sci Rep,2020(10):20314. [19]Moruno-Manchon JF,Uzor NE,Blasco-Conesa MP,et al.Inhibiting sphingosine kinase 2 mitigates mutant Huntingtin-induced neurodegeneration in neuron models of Huntington disease[J].Human Molecular Genetics,2017,26(7):1305-1317. [20]Song DD,Zhou JH,Sheng R.Regulation and function of sphingosine kinase 2 in diseases[J].Histology&Histopathology,2017(33):433-445. [21]Weigert A,Knethen AV,Thomas D,et al.Sphingosine kinase 2 is a negative regulator of inflammatory macrophage activation[J].Biochimica et Biophysica Acta(BBA)- Molecular and Cell Biology of Lipids,2019,1864(9):1235-1246. [22]Imeri F,Schwalm S,Lyck R,et al.Sphingosine kinase 2 deficient mice exhibit reduced experimental autoimmune encephalomyelitis:Resistance to FTY720 but not ST-968 treatments[J].Neuropharmacology,2016(105):341-350. [23]Yang G,Gu M,Chen W,et al.SPHK-2 Promotes the Particle-Induced Inflammation of RAW264.7 by Maintaining Consistent Expression of TNF-α and IL-6[J].Inflammation,2018,41(9855):1-10. [24]Gaire BP.Sphingosine kinase 2 as the promising target for stroke research[J].Int J Stroke,2018,13(4):NP11-NP12.

更新日期/Last Update: 1900-01-01